@article{fedd3c573ac14796969784222d108383,
title = "Therapygenetic effects of 5-HTTLPR on cognitive-behavioral therapy in anxiety disorders: A meta-analysis",
abstract = "There is a recurring debate on the role of the serotonin transporter gene linked polymorphic region (5-HTTLPR) in the moderation of response to cognitive behavioral therapy (CBT) in anxiety disorders. Results, however, are still inconclusive. We here aim to perform a meta-analysis on the role of 5-HTTLPR in the moderation of CBT outcome in anxiety disorders. We investigated both categorical (symptom reduction of at least 50%) and dimensional outcomes from baseline to post-treatment and follow-up. Original data were obtained from ten independent samples (including three unpublished samples) with a total of 2,195 patients with primary anxiety disorder. No significant effects of 5-HTTLPR genotype on categorical or dimensional outcomes at post and follow-up were detected. We conclude that current evidence does not support the hypothesis of 5-HTTLPR as a moderator of treatment outcome for CBT in anxiety disorders. Future research should address whether other factors such as long-term changes or epigenetic processes may explain further variance in these complex gene-environment interactions and molecular-genetic pathways that may confer behavioral change following psychotherapy. Crown Copyright (C) 2021 Published by Elsevier B.V. All rights reserved.",
keywords = "CBT, Panic disorder, Serotonin transporter gene, Therapy outcome, Therapygenetics, Treatment response, cbt, panic disorder, serotonin transporter gene, therapy outcome, therapygenetics, treatment response, DEPRESSION, ENVIRONMENT INTERACTION, PANIC DISORDER, CHILDHOOD TRAUMA, SEROTONIN TRANSPORTER GENE, PROMOTER POLYMORPHISM 5-HTTLPR, TREATMENT RESPONSE, STRESS, ASSOCIATION, LIFE EVENTS",
author = "M.A. Schiele and A. Reif and J.X. Lin and G.W. Alpers and E. Andersson and G. Andersson and V. Arolt and J. Bergstrom and P. Carlbring and T.C. Eley and G. Esquivel and T. Furmark and A.L. Gerlach and A. Hamm and S. Helbig-Lang and J.L. Hudson and T. Lang and K.J. Lester and N. Lindefors and T.B. Lonsdorf and P. Pauli and J. Richter and W. Rief and S. Roberts and C. Ruck and K.R.J. Schruers and C. Thiel and H.U. Wittchen and K. Domschke and H. Weber and U. Lueken",
note = "Funding Information: This work was supported by the German Research Foundation (DFG) – Project No. 44541416 – TRR 58, projects C02 (to KD), C09 (to UL) and Z02 (to AR, KD, PP, TBL and UL), SFB 1193 Z03 (to AR), and the German Ministry of Research and Education (BMBF, 01EE1402F , PROTECT-AD, P5 to KD). Funding Information: AR reports speaker honoraria and advisory board honoraria from Janssen, Servier, Medice, Shire and neuraxpharm. VA has received compensations for his contributions as member of advisory boards and for presentations for the following companies: Astra-Zeneca, Eli Lilly, Janssen-Cilag, Lundbeck, Otsuka, Sanofi, Servier, and Trommsdorff. TCE is part funded by a program grant from the UK Medical Research Council (MR/M021475/1), and the National Institute for Health Research (NIHR) Biomedical Research center at South London and Maudsley NHS Foundation Trust and King's College London. The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health. PP reports having received research funding from Volkswagenstiftung (A124277) and that he is shareholder of a commercial company (VTplus) that develops virtual reality research systems. KD is a member of the Janssen Pharmaceuticals, Inc. Steering Committee Neurosciences. All other authors reported no biomedical financial interests or potential conflicts of interest. Funding Information: This work was partly funded by a grant from the UK Medical Research Council to TC Eley ( G0901874 ). Funding Information: The study is in part funded by the German Federal Ministry of Education and Research (BMBF, 01GV0614 ) as part of the larger BMBF Psychotherapy Research Funding Initiative Improving the Treatment of Panic Disorder. Publisher Copyright: {\textcopyright} 2021",
year = "2021",
month = mar,
day = "1",
doi = "10.1016/j.euroneuro.2021.01.004",
language = "English",
volume = "44",
pages = "105--120",
journal = "European Neuropsychopharmacology",
issn = "0924-977X",
publisher = "Elsevier",
}